The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC). The research identified enolase 2 (ENO2), a ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase I ...